Profound Medical Gets Bullish Call From Stifel -- Market Talk

Dow Jones07-16

1113 ET - Shares in Profound Medical are sharply higher following a Stifel upgrade to buy from hold. Analysts cite an announcement from the Centers for Medicare and Medicaid Services proposing what they call "first-time-ever, competitive TULSA procedure-specific reimbursement." TULSA, developed by Profound Medical, is a minimally invasive, incision-free procedure that uses ultrasound to treat prostate cancer. The analysts expect CMS will confirm/finalize these initial reimbursement proposals in late October/early November. While the company still has considerable operational, commercial, and clinical work ahead to further the treatment's market share, the CMS reimbursement marks a critical milestone, the analysts add. Stifel raises the target price to $12 from $9. Profound Medical surges 9.3% to $10. (don.forbes@wsj.com)

(END) Dow Jones Newswires

July 16, 2024 11:14 ET (15:14 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2451190919?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-16 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2451190919","market":"sh","top_or_hot":-1,"title":"Profound Medical Gets Bullish Call From Stifel -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1113 ET - Shares in Profound Medical are sharply higher following a Stifel upgrade to buy from hold. Analysts cite an announcement from the Centers for Medicare and Medicaid Services proposing what they call \"first-time-ever, competitive TULSA procedure-specific reimbursement.\" TULSA, developed by Profound Medical, is a minimally invasive, incision-free procedure that uses ultrasound to treat prostate cancer. The analysts expect CMS will confirm/finalize these initial reimbursement proposals in late October/early November. While the company still has considerable operational, commercial, and clinical work ahead to further the treatment's market share, the CMS reimbursement marks a critical milestone, the analysts add. Stifel raises the target price to $12 from $9. Profound Medical surges 9.3% to $10. (don.forbes@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 16, 2024 11:14 ET (15:14 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Profound Medical Gets Bullish Call From Stifel -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProfound Medical Gets Bullish Call From Stifel -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-16 23:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1113 ET - Shares in Profound Medical are sharply higher following a Stifel upgrade to buy from hold. Analysts cite an announcement from the Centers for Medicare and Medicaid Services proposing what ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4127","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2451190919","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2451190919","pubTimestamp":1721142840,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1113 ET - Shares in Profound Medical are sharply higher following a Stifel upgrade to buy from hold. Analysts cite an announcement from the Centers for Medicare and Medicaid Services proposing what they call \"first-time-ever, competitive TULSA procedure-specific reimbursement.\" TULSA, developed by Profound Medical, is a minimally invasive, incision-free procedure that uses ultrasound to treat prostate cancer. The analysts expect CMS will confirm/finalize these initial reimbursement proposals in late October/early November. While the company still has considerable operational, commercial, and clinical work ahead to further the treatment's market share, the CMS reimbursement marks a critical milestone, the analysts add. Stifel raises the target price to $12 from $9. Profound Medical surges 9.3% to $10. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4127":"投资银行业与经纪业","PROF":"Profound Medical Corp.","SF":"Stifel Financial Corp","BK4082":"医疗保健设备"},"translate_title":"Profound Medical获得Stifel的看涨看涨期权——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SF":1,"PROF":0.9},"content_text":"1113 ET - Shares in Profound Medical are sharply higher following a Stifel upgrade to buy from hold. Analysts cite an announcement from the Centers for Medicare and Medicaid Services proposing what they call \"first-time-ever, competitive TULSA procedure-specific reimbursement.\" TULSA, developed by Profound Medical, is a minimally invasive, incision-free procedure that uses ultrasound to treat prostate cancer. The analysts expect CMS will confirm/finalize these initial reimbursement proposals in late October/early November. While the company still has considerable operational, commercial, and clinical work ahead to further the treatment's market share, the CMS reimbursement marks a critical milestone, the analysts add. Stifel raises the target price to $12 from $9. Profound Medical surges 9.3% to $10. (don.forbes@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  July 16, 2024 11:14 ET (15:14 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451190919"}